Novo Nordisk Threatens Legal Action Against Hims & Hers Over Compounded Wegovy Pill
Synopsis
Earlier in the day, Hims launched a copy of the Wegovy pill priced at $49 per month, much below the branded drug.
Danish drugmaker Novo Nordisk (NVO) said on Thursday that it will pursue “legal and regulatory” actions against Hims & Hers (HIMS) after the latter launched a compounded copy of Novo’s best-selling weight loss pill.
Earlier in the day, Hims launched a copy of the Wegovy pill priced at $49 per month, much below the branded drug.
“This is another example of Hims & Hers' historic behaviour of duping the American public with knock-off GLP-1 products,” Novo said in a statement.
NVO shares traded 7% lower at the time of writing, while HIMS stock pared gains made earlier in the day to trade about 1% higher.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.